Although certain immune checkpoints, including CD274 (PD-L1), PDCD1 (PD-1), and CTLA-4, have been effectively employed in targeted immunotherapy for other organ tumors [44], this study explored that the expression of these molecules was notably low in gliomas. The gene discussed is CTLA4; the disease is glioma.